作者
Luis Ortega Paz, Wilbert Bor, Francesco Franchi, Wout Van Den Broek, Fabiana Rollini, SALVATORE GIORDANO, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Haroutioun Garabedian, Tala Al Saleh, Ekin Can Uzunoglu, Xuan Zhou, Andrea Rivas, Andres M Pineda Maldonado, Siva Suryadevara, Daniel Soffer, Martin M Zenni, Jurrien M Ten Berg, Dominick J Angiolillo
发表日期
2024/4/2
期刊
Journal of the American College of Cardiology
卷号
83
期号
13_Supplement
页码范围
847-847
出版商
American College of Cardiology Foundation
简介
Background
Dual antithrombotic therapy (DAT) with clopidogrel and a novel oral anticoagulant (NOAC) is the treatment of choice in patients undergoing PCI who require oral anticoagulation. However, there are concerns for subjects with impaired clopidogrel response, suggesting alternative treatment (eg, ticagrelor) in these patients.
Methods
This was a prospective, randomized study performed in patients on a NOAC treated with PCI. Patients with impaired clopidogrel response, identified by an ABCD-GENE score*≥ 10, were randomized to ticagrelor (60 mg/bid) or clopidogrel (75 mg/qd). Patients with an ABCD-GENE< 10 were treated with clopidogrel (75 mg/qd; control cohort). The primary endpoint was trough P2Y 12 reactive units [PRU] at 30 days.
Results
A total of 67 patients were enrolled; 33 had an ABCD-GENE score≥ 10 and were randomized; 34 had an ABCD-GENE< 10 (control arm). At 30 days, PRU …
学术搜索中的文章
LO Paz, W Bor, F Franchi, W Van Den Broek, F Rollini… - Journal of the American College of Cardiology, 2024